Head to Head Comparison: Fonar (NASDAQ:FONR) and Global Wholehealth Partners (OTCMKTS:GWHP)

Global Wholehealth Partners (OTCMKTS:GWHP) and Fonar (NASDAQ:FONR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

50.6% of Fonar shares are owned by institutional investors. 10.3% of Global Wholehealth Partners shares are owned by company insiders. Comparatively, 1.6% of Fonar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Global Wholehealth Partners and Fonar”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Wholehealth Partners	N/A	N/A	N/A	N/A	N/A
Fonar	$104.35 million	0.88	$8.33 million	$1.11	13.29

Fonar has higher revenue and earnings than Global Wholehealth Partners.

Profitability

This table compares Global Wholehealth Partners and Fonar’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Wholehealth Partners	N/A	N/A	N/A
Fonar	7.08%	4.66%	3.48%

Analyst Ratings

This is a summary of current recommendations for Global Wholehealth Partners and Fonar, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Wholehealth Partners	0	0	0	0	0.00
Fonar	0	1	0	0	2.00

Given Global Wholehealth Partners’ higher possible upside, research analysts plainly believe Global Wholehealth Partners is more favorable than Fonar.

Summary

Fonar beats Global Wholehealth Partners on 6 of the 8 factors compared between the two stocks.

About Global Wholehealth Partners

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.

About Fonar

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.